Workflow
AngioDynamics(ANGO)
icon
Search documents
AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval
zacks.com· 2024-05-22 17:21
AngioDynamics, Inc. (ANGO) recently announced the European CE Mark approval for its AlphaVac F1885 System for the non-surgical removal of thrombi or emboli from the pulmonary arteries and the treatment of pulmonary embolism (PE).The application of the AlphaVac F1885 System in the non-surgical excision of thrombi or emboli from the venous vasculature is enhanced by the CE Mark approval, which is likely a significant step forward in improving patient care and safety for endovascular therapies in the EU, a mar ...
AngioDynamics(ANGO) - 2024 Q3 - Quarterly Report
2024-04-09 21:08
Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | |--------------------------------------------------------------------------------------------| | For the transition period from to Commission file number 0-50761 | | AngioD ...
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
Zacks Investment Research· 2024-04-05 16:56
AngioDynamics, Inc. (ANGO) reported an adjusted loss per share of 16 cents for third-quarter fiscal 2024, wider than the year-ago loss of 3 cents per share and the Zacks Consensus Estimate of a loss of 14 cents per share.On a pro-forma basis (excluding Dialysis and BioSentry businesses, the divested PICC and Midline product portfolios and the discontinued Uniblate, Starburst and Syntrax products), adjusted loss per share in third-quarter fiscal 2024 was also 16 cents, wider than the adjusted loss per share ...
AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment
Zacks Investment Research· 2024-04-05 16:46
AngioDynamics, Inc. (ANGO) recently announced the FDA 510(k) clearance for its AlphaVac F1885 System for the treatment of pulmonary embolism (PE).The application of the AlphaVac F1885 System in the non-surgical excision of thrombi or emboli from the venous vasculature is increased by the enhanced FDA indication, which permits the system to be used for PE therapy. By lowering the thrombus burden and enhancing right ventricular function, the indication broadens the range of therapy alternatives available to P ...
AngioDynamics(ANGO) - 2024 Q3 - Earnings Call Transcript
2024-04-04 15:11
Financial Data and Key Metrics Changes - The company reported revenue of $66 million for Q3 FY24, representing an 8% year-over-year growth, with med tech segment growth of nearly 13% and med device segment growth of 5% [10][20] - Adjusted net loss for Q3 FY24 was $6.5 million, or adjusted loss per share of $0.16, compared to an adjusted net loss of $5.4 million or adjusted loss per share of $0.14 in the same quarter last year [26] - GAAP net loss for Q3 FY24 was $190.4 million, including a goodwill impairment charge of $159.5 million [27] Business Line Data and Key Metrics Changes - Med tech revenue was $25.7 million, a 12.6% year-over-year increase, while med device revenue was $40.3 million, growing 5.2% compared to Q3 FY23 [20] - Auryon platform contributed $11.8 million in revenue during Q3, growing 14.7% year-over-year [21] - NanoKnife disposable revenue increased 19.8% year-over-year, with capital sales growing 230.9% [22] Market Data and Key Metrics Changes - International business grew approximately 21% year-over-year, with med tech growing 53% and med device growing 7% [16] - The company expects to initiate a limited launch of AlphaVac for pulmonary embolism treatment by the end of Q4 FY24, with a full launch scheduled for Q1 FY25 [12][13] Company Strategy and Development Direction - The company is focused on optimizing its portfolio, having divested its PICC and midline product portfolios for up to $45 million, with $30 million received in Q3 [17] - The transition to a fully outsourced manufacturing model is underway, expected to generate approximately $15 million in annualized savings starting in FY26 [18][24] - The company aims to drive growth from key med tech platforms while expanding margins and moving towards profitability [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth strategy, highlighting the FDA clearance for AlphaVac as a significant milestone [12] - The company anticipates FY24 revenue in the range of $270 million to $275 million, reflecting the impact of recent divestitures [32] - Management noted that there are no significant market changes affecting guidance, maintaining a consistent outlook despite operational transitions [42] Other Important Information - The company has zero debt compared to $50 million a year ago, significantly strengthening its balance sheet [28][30] - A settlement agreement with BD Bard was reached, resolving over a decade of IP litigation, providing clarity and allowing the company to focus on growth [31] Q&A Session Summary Question: When will data from the APEX trial be available? - Management indicated that data will be released at upcoming trade shows and through publications from principal investigators [36] Question: What are the rollout plans for AlphaVac in PE? - The company has prepared its sales force and will conduct a limited market release followed by a larger launch [48] Question: Will there be any changes in guidance due to recent divestitures? - Management confirmed that guidance remains consistent, reflecting the divestiture's impact without significant market changes [42] Question: What is the pricing strategy for AlphaVac? - The expected price for AlphaVac is around $9,000 [60] Question: How is the NanoKnife performing and when will PRESERVE data be available? - The NanoKnife is seeing strong growth, particularly in prostate treatments, with data from the PRESERVE study expected to be published following the 12-month follow-up [62]
AngioDynamics(ANGO) - 2024 Q3 - Quarterly Results
2024-04-04 11:30
Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture Fiscal Year 2024 Third Quarter Highlights • Completed the sale of its PICC and Midline product portfolios to Spectrum Vascular on February 15, 2024 o Discontinued its Uniblate and Starburst RadioFrequency products, as well as its Syntrax support ...
AngioDynamics (ANGO) Settles Patent Litigations With BD
Zacks Investment Research· 2024-04-02 15:36
AngioDynamics, Inc. (ANGO) recently announced that it has entered into a settlement agreement with Becton, Dickinson and Company (BDX) , popularly known as BD, to resolve all outstanding patent litigation with C.R. Bard, Inc., an affiliate of BD.AngioDynamics is likely to benefit from the settlement of this prolonged legal dispute to a successful resolution as it will lower the company’s ongoing legal expenses and terminate more than 10-year distraction.Price PerformanceFor the past six months, ANGO’s share ...
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024
Businesswire· 2024-03-19 20:01
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market open on Thursday, April 4, 2024. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the ...
AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors
Zacks Investment Research· 2024-03-15 23:21
The most recent trading session ended with AngioDynamics (ANGO) standing at $5.37, reflecting a -0.74% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's daily loss of 0.65%. Meanwhile, the Dow experienced a drop of 0.49%, and the technology-dominated Nasdaq saw a decrease of 0.96%.The medical device maker's stock has dropped by 12.32% in the past month, falling short of the Medical sector's gain of 1.98% and the S&P 500's gain of 3.27%.The upcoming earnings relea ...
Why AngioDynamics (ANGO) Dipped More Than Broader Market Today
Zacks Investment Research· 2024-03-09 00:16
AngioDynamics (ANGO) closed at $5.67 in the latest trading session, marking a -1.39% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.65% for the day. On the other hand, the Dow registered a loss of 0.18%, and the technology-centric Nasdaq decreased by 1.16%.The the stock of medical device maker has fallen by 6.5% in the past month, lagging the Medical sector's gain of 3.18% and the S&P 500's gain of 3.4%.The investment community will be paying close attention to th ...